Celgene has filed a lawsuit against Indian drugs manufacturer Dr Reddy’s Laboratories (DRL) to halt its plan to produce and market generic versions of Pomalyst (pomalidomide)—Celgene’s multiple myeloma treatment.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
25 April 2023 New Jersey judge denies motion to stay antitrust action regarding blockbuster cancer drug | Defendants had argued litigation would be unnecessary and costly.
27 June 2022 India-based Dr Reddy’s has ended its litigation with Indivior and Aquestive Therapeutics over a generic version of opioid addiction treatment Suboxone sublingual film.
1 February 2022 Bristol-Myers Squibb subsidiary, Celgene has settled its lawsuit against India-based drug maker Dr Reddy's over a generic version of the blockbuster cancer treatment, Pomalyst.